# Sacituzumab Govitecan
ตอนพอดคาสต์ยอดนิยม
อัปเดตแล้ว:
sacituzumab govitecan, sold under the brand name Trodelvy by Gilead Sciences, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer, previously treated metastatic hormone receptor–positive, HER2-negative breast cancer, and metastatic urothelial cancer.
The most common side effects include nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia (hair loss), constipation, decreased appetite, rash and abdominal pain. sacituzumab govitecan has a boxed warning about the risk of severe neutropenia (abnormally low levels of white blood cells) and severe diarrhea.
Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Featuring an interview with Dr Kevin Kalinsky, including the following topics:
Prophylaxis, Monitoring and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (0:00)
Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and insti…
Dr. Bill Gradishar & Dr. Tiffany Traina - Is First-Line mTNBC Changing? Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained
In this deep-dive conversation, Dr. Bill Gradishar and Dr. Tiffany Traina break down two pivotal first-line trials reshaping treatment for metastatic triple-negative breast cancer.
They explore TROPION-Breast02 and ASCENT-03, unpacking progression-free survival, overall survival, response rates, t…
Program Director's Choice from SABCS2025 - Part 2: Sacituzumab Govitecan for Endocrine Therapy-refractory Advanced Breast Cancers
Kate Lathrop, MD discuss one of the high impact, clinically relevant, clinical trial, the ASCENT-07 trial that were presented at the San Antonio Breast Cancer Symposium 2025.
Video: https://medicaldigest.org/scientific-contents/interview:program-directors-choice-sabcs2025-part-2-sacituzumab-govitec…
Sacituzumab Govitecan: Advancing the Role of ADCs in Breast Cancer
In this episode of OncoTalks, host Tulsi Patel speaks with Dr. Hope Rugo about the evolving role of antibody‑drug conjugates (ADCs) in breast cancer, with a focus on sacituzumab govitecan, the first and currently only approved ADC for patients with previously treated metastatic triple‑negative brea…
Can the Use of ADCs in Breast Cancer Teach Us About Resistance Mechanisms and Sequencing in Endometrial Cancer?
Drs Ursula A. Matulonis and Leif W. Ellisen discuss endometrial cancer and ADCs, including resistance mechanisms, ADC sequencing, what's exciting in the field, and novel payloads.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-end…
Kevin Kalinsky MD; ASCO 2026: ASCENT-04 Study Finds Sacituzumab Govitecan plus Pembrolizumab Helps Patients with Previously Untreated Metastatic PD-L1 Positive Triple Negative Breast Cancer Live Longer Without Progression Beyond Subsequent Therapies
CHICAGO, USA—Combining the antibody-drug conjugate sacituzumab govitecan with pembrolizumab immunotherapy for patients with metastatic triple-negative breast cancers testing positive for the programmed death-ligand 1 (PD-L1) led to significant delays of disease progression after subsequent therapy …
New First-Line Treatment: Metastatic Triple-Negative Breast Cancer with Dr. Sara Tolaney
This episode is sponsored by Gilead Sciences. Gilead had no involvement or input in the podcast content. Gilead is working to transform how cancer is treated. We are innovating with next-generation therapies, combinations, and technologies to deliver improved outcomes for people with cancer. From a…
Oncology News: mRNA Cancer Vaccine Milestone & New Pancreatic Cancer Approval
🎥 Latest Oncology News
From a landmark mRNA-based individualized neoantigen therapy result in melanoma to an important advance in metastatic pancreatic cancer, this edition brings several major developments across oncology.
Dr. Stephanie Haddad, Hematology/Oncology Fellow and Academic Chief Fellow …
First-Line Treatment for Metastatic TNBC: Inside the ASCENT-03 Trial | Dr. Alissa Huston, University of Rochester
This episode is sponsored by Gilead Sciences. Gilead had no involvement or input in the podcast content. Gilead is working to transform how cancer is treated. We are innovating with next-generation therapies, combinations, and technologies to deliver improved outcomes for people with cancer. From a…
เครื่องมือค้นหาพอดแคสต์
คุณสามารถใช้เว็บไซต์ของเราเพื่อค้นหาพอดแคสต์ของ3,826,057และตอนของ195,988,214ตามบุคคล สถานที่ หรือหัวข้อ
การลงทุนในความรู้ให้ผลตอบแทนดีที่สุด ฉันจึงฟังพอดแคสต์
‐ Benjamin "Llamacorn" Franklin
